Amicus Therapeutics EBITDA 2010-2022 | FOLD

Amicus Therapeutics ebitda from 2010 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Amicus Therapeutics Annual EBITDA
(Millions of US $)
2021 $-198
2020 $-236
2019 $-297
2018 $-314
2017 $-429
2016 $-176
2015 $-129
2014 $-67
2013 $-62
2012 $-51
2011 $-49
2010 $-54
2009 $-5
Amicus Therapeutics Quarterly EBITDA
(Millions of US $)
2022-03-31 $-73
2021-12-31 $-70
2021-09-30 $-40
2021-06-30 $-37
2021-03-31 $-51
2020-12-31 $-62
2020-09-30 $-50
2020-06-30 $-49
2020-03-31 $-76
2019-12-31 $-87
2019-09-30 $-56
2019-06-30 $-75
2019-03-31 $-79
2018-12-31 $-65
2018-09-30 $-153
2018-06-30 $-43
2018-03-31 $-53
2017-12-31 $-64
2017-09-30 $-272
2017-06-30 $-44
2017-03-31 $-49
2016-12-31 $-44
2016-09-30 $-42
2016-06-30 $-48
2016-03-31 $-42
2015-12-31 $-41
2015-09-30 $-38
2015-06-30 $-27
2015-03-31 $-24
2014-12-31 $-22
2014-09-30 $-16
2014-06-30 $-14
2014-03-31 $-15
2013-12-31 $-15
2013-09-30 $-15
2013-06-30 $-16
2013-03-31 $-17
2012-12-31 $-16
2012-09-30 $-16
2012-06-30 $-9
2012-03-31 $-10
2011-12-31 $-13
2011-09-30 $-13
2011-06-30 $-14
2011-03-31 $-10
2010-12-31 $-17
2010-09-30 $-13
2010-06-30 $-12
2010-03-31 $-13
2009-12-31 $33
2009-09-30 $-13
2009-06-30 $-13
2009-03-31 $-12
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.126B $0.306B
Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.?The company has one marketed medicine in its portfolio named Galafold which is the first and the only approved oral precision medicine for patients living with Fabry disease, having amenable genetic variants. Migalastat is a potent orally available inhibitor of alpha-Gal A.?The drug was granted an accelerated approval by the FDA for treating adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant. Galafold is the first and only oral therapy approved in the EU for the long-term treatment of adolescents with Fabry disease.?The lead pipeline candidate in the company's portfolio is AT-GAA, a differentiated biologic for Pompe disease. The company has one gene-therapy program in its pipeline CLN3, a type of Batten disease, being evaluated in a phase I/II study.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00